Annual Drug Patent Expirations for TRINTELLIX
Trintellix is a drug marketed by Takeda Pharms Usa and is included in one NDA. It is available from three suppliers. There are ten patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for TRINTELLIX.
This drug has one hundred and ninety-four patent family members in forty-one countries.
The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. Three suppliers are listed for this compound. Additional details are available on the vortioxetine hydrobromide profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
